Screener
Castle Biosciences CSTL Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| ASSETS | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Accounts receivable, net | 42,264 | 43,382 |
| Inventory | 10,461 | 10,254 |
| Prepaid expenses and other current assets | 14,491 | 7,956 |
| Total current assets | 328,901 | 361,097 |
| Long-term accounts receivable, net | 1,921 | 1,878 |
| Property and equipment, net | 100,934 | 97,443 |
| Operating lease assets | 14,424 | 14,795 |
| Goodwill and other intangible assets, net | 97,347 | 99,574 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's total current assets?
- Castle Biosciences (CSTL) reported total current assets of $328.9M in Q1 2026.
- How has Castle Biosciences's total current assets changed year-over-year?
- Castle Biosciences's total current assets decreased by 5.9% year-over-year, from $349.39M to $328.9M.
- What is the long-term trend for Castle Biosciences's total current assets?
- Over 5 years (2020 to 2025), Castle Biosciences's total current assets has grown at a -3.4% compound annual growth rate (CAGR), from $429.59M to $361.1M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Castle Biosciences's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude